The ankylosing spondylitis market reached a value of USD 5.1 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 10.2 Billion by 2035, exhibiting a growth rate (CAGR) of 6.53% during 2025-2035. This can be attributed to the rising popularity of numerous innovative approaches to treatment, including combination therapy in patients who have failed other medications.
Ankylosing spondylitis (AS) represents a chronic inflammatory disease that largely affects the joints of the spine, leading to stiffness and pain. The ankylosing spondylitis market is primarily driven by the increasing prevalence of autoimmune diseases, advancements in biologic and targeted therapies, and growing awareness about early diagnosis and disease management. Besides this, the widespread adoption of tumor necrosis factor (TNF) inhibitors and interleukin-17 (IL-17) inhibitors has significantly improved patient outcomes, fueling the ankylosing spondylitis market growth. The rising preference for biosimilars, which offer cost-effective alternatives to branded biologics, is further expanding treatment accessibility, particularly in emerging markets.
Moreover, continuous research and development (R&D) efforts are leading to the introduction of novel small-molecule drugs, such as Janus kinase (JAK) inhibitors, which provide new treatment options for patients who do not respond to traditional biologics, thereby catalyzing the ankylosing spondylitis market expansion. In parallel, government initiatives and healthcare reimbursement policies are improving patient access to advanced therapeutics. Additionally, the integration of artificial intelligence (AI) and machine learning (ML) in drug discovery and precision medicine is accelerating the development of personalized treatment approaches, thus stimulating the ankylosing spondylitis market growth. Furthermore, the trend towards precision medicine, which tailors therapies based on genetic and molecular profiling, is anticipated to propel the expansion of the ankylosing spondylitis market in the coming years.
π«πππππππ πΊπππππ π·π«π πͺπππ:: https://www.imarcgroup.com/ankylosing-spondylitis-market/requestsample
The report also provides a detailed analysis of the current ankylosing spondylitis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
ππ±π©π₯π¨π«π Full πππ©π¨π«π π°π’ππ‘ πππ – Ankylosing Spondylitis Treatment Market Epidemiology
Countries Covered
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Competitive Landscape:
The competitive landscape of the ankylosing spondylitis market has been studied in the report with the detailed profiles of the key players operating in the market.
AbbVie
Pfizer
Eli Lilly and Company
Janssen Biotech
Novartis Pharmaceutical
UCB
Akeso Biopharma
About Us:
IMARC Group is a global management consulting firm that helps the worldβs most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
Market Outlook 